BioWorld MedTech: The Daily Medical Technology News Source
WEBBioWorld Premium. Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription. Daily news and analysis of the medical technology industry. In-depth coverage of business, financing, regulation, science, innovation, device approvals, clinical trials and more.
Novo Nordisk wins first FDA approval for long-acting human
WEBSep 1, 2020 · The first weekly therapy for adult growth hormone deficiency (GHD) has arrived in the U.S. with FDA approval for Novo Nordisk A/S' Sogroya (somapacitan). It’s the first of Novo's regulatory filings for the medicine, also submitted in the EU and Japan, to win approval. Growth hormone deficiency is characterized by inadequate growth hormone production from the anterior pituitary gland.
Today's news in brief | BioWorld
WEBSep 16, 2024 · Today's news in brief. Sep. 6, 2024. BioWorld briefs for Sept. 6, 2024. BioWorld Briefs. Cumulus raising $50M, spinning GPR68 small molecules into GIO. Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of sourcing novel drug targets emerging from academia, shaping them up...
Getinge to acquire Paragonix for $477M | BioWorld
WEBAug 23, 2024 · Getinge AB agreed to acquire Paragonix Technologies Inc. for $477 million, including upfront and earn out payments. The deal marks Getinge’s entry into the global organ preservation and transportation market, a rapidly advancing field driven by rising transplant volumes, technological innovations and evolving clinical practices.
China - BioWorld
WEB3 days ago · Sep. 17, 2024. By Marian (YoonJee) Chu. No Comments. Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster therapies in China. At the heart of the GLP-1 boom is a nationwide obesity problem driven by a ...
Telix expands US radiopharma footprint with $250M RLS buy
WEB2 days ago · Sep. 24, 2024. By Tamra Sami. Radiopharmaceutical company Telix Pharmaceuticals Ltd. is continuing its buying spree to shore up dominance in the radiopharmaceutical market with its latest acquisition of RLS Radiopharmacies for $250 million to expand its U.S. manufacturing presence and establish a next-generation radiometal production network.
Stem cells eat dead cells to ensure tissue integrity | BioWorld
WEBAug 27, 2024 · Phagocytosis – eliminating millions of dead cells every day – requires specialized cells such as macrophages, the true professionals, which migrate to engulf waste and dying cells. But they are not the only ones that can perform this task, as scientists at Howard Hughes Medical Institute (HHMI) discovered when they investigated hair follicle stem cells (HFSCs), a tissue in constant ...
Two enzymatic modulators could alleviate Gaucher disease
WEBAug 26, 2024 · People with the rare inherited metabolic disorder Gaucher disease have a deficiency in the lipid-digesting glucocerebrosidase enzyme, which causes the accumulation of harmful levels of glucolipids in various organs. The enzyme has a very short half-life, which rules out enzyme replacement as an effective therapy, and as things stand, there are few treatments for this and other lysosomal ...
Vutrisiran phase III boosts Alnylam; biopharma index outperforms
WEBAug 20, 2024 · The BioWorld Biopharmaceutical Index climbed 16.31% by the end of July, continuing its lead over both the Nasdaq Biotechnology Index, which rose 10.82%, and the Dow Jones Industrial Average, up 8.37%. This follows an 8.15% gain in the BBI at the close of May, marking a strong performance throughout 2024.
Mutated tumor suppressors may become oncogenes, potential
WEBAug 23, 2024 · Mutated tumor suppressors may become oncogenes, potential drug targets. A new study has shown that when a gene is mutated and its copy number is altered, the risk of that gene contributing to the development of cancer increases. Although it was already known that both variations together promoted cancer, …